Patients with a DLT by tested compound category for phase 1 trials

	N	Proportion	95%−CI	Effect size
Antiangiogenesis	15	6.6	(3.8; 11.3)	
Chemotherapy	18	10.4	(6.6; 16.1)	
Immunomodulator	21	5.3	(3.6; 7.7)	
Other	14	17.4	(11.7; 25.1)	
Receptor or signal transduction	81	10.7	(8.8; 13.1)	
Vaccine	8	3.4	(1.3; 8.6)	
Overall	157	9.8	(8.4; 11.4)	
Prediction interval			(2.3; 33.2)	

Effect size (95%−CI)

Test for subgroup differences: p < 0.001